Cefixime

Generic Name: Cefixime

Brand Names: Suprax

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₅N_₅O_₇S_₂

CAS Number: 79350-37-1

Unique Ingredient Identifier: XZ7BG04GJX

Background: Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results fro...

Indication: For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis, (2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-l...

Associated Conditions: Acute Exacerbation of Chronic Bronchitis caused by Streptococcus Pneumoniae, Acute Exacerbations of Chronic Bronchitis caused by Haemophilus Influenzae, Bacterial Sinusitis, Community Acquired Pneumonia (CAP), Gonorrhea of anus, Lyme Disease, Salmonella Infections, Shigella Infection, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated Urinary Tract Infections, Bacterial otitis media, Bacterial rhinosinusitis, Disease caused by Salmonella typhi, Uncomplicated Gonorrhea

Associated Therapies: -

Clinical Trials

Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea

Phase 4

Completed

Conditions: Gonorrhea

Interventions: Drug: Ceftriaxon
Drug: Cefixime
Drug: Doxycyclin
Drug: Azithromycin

First Posted Date: 2023-10-19

Last Posted Date: 2023-10-23

Lead Sponsor: Bulovka Hospital

Target Recruit Count: 161

Registration Number: NCT06090565

Locations: 🇨🇿
University Hospital Bulovka, Prague, Czechia
🇨🇿
Venereology Prague, Medicentrum Beroun, Prague, Czechia

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Phase 2

Recruiting

Conditions: Gonorrhea Male

Interventions: Drug: Cefixime
Drug: Ceftriaxone
Drug: Ciprofloxacin
Biological: Neisseria gonorrhoeae strain FA1090
Biological: Meningococcal Group B Vaccine
Biological: Influenza Vaccine
Biological: Tetanus-diptheria Vaccine

First Posted Date: 2022-03-24

Last Posted Date: 2023-05-24

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 140

Registration Number: NCT05294588

Locations: 🇺🇸
Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research North, Chapel Hill, North Carolina, United States

The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)

Phase 4

Recruiting

Conditions: Typhoid Fever

Interventions: Drug: Azithromycin
Drug: Cefixime
Drug: Placebo

First Posted Date: 2020-04-16

Last Posted Date: 2023-12-06

Lead Sponsor: Oxford University Clinical Research Unit, Vietnam

Target Recruit Count: 1500

Registration Number: NCT04349826

Locations: 🇳🇵
Patan Hospital, Lalitpur, Bagmati, Nepal

Ciprofloxacin Plus Metronidazole Vs Cefixime Plus Metronidazole Therapy for the Treatment of Liver Abscess

Phase 3

Conditions: Liver Abscess

Interventions: Drug: Ciprofloxacin
Drug: Cefixime

First Posted Date: 2019-05-31

Last Posted Date: 2019-07-22

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 140

Registration Number: NCT03969758

Locations: 🇮🇳
Post Graduate Institute of Medical Education and Research, Chandigarh, India

Experimental Human Infection With Neisseria Gonorrhoeae

Phase 1

Completed

Conditions: Gonococcal Infection

Interventions: Drug: Cefixime
Drug: Ceftriaxone
Drug: Ciprofloxacin
Biological: Neisseria gonorrhoeae strain FA7537
Biological: Neisseria gonorrhoeae strain FA1090 A26

First Posted Date: 2019-02-15

Last Posted Date: 2021-03-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT03840811

Locations: 🇺🇸
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States

Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis in Non-pregnant Women

Phase 1

Conditions: Syphilis Female

Interventions: Drug: Cefixime
Drug: Benzathine penicillin 2.4 million units

First Posted Date: 2018-11-23

Last Posted Date: 2020-02-05

Lead Sponsor: World Health Organization

Target Recruit Count: 180

Registration Number: NCT03752112

Locations: 🇧🇷
Fortaleza University, Fortaleza, Ceara, Brazil

Cefixime / Azithromycin pK Study

Phase 1

Completed

Conditions: Gonorrhoea

Interventions: Drug: Azithromycin
Drug: Cefixime

First Posted Date: 2016-03-15

Last Posted Date: 2017-09-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT02708992

Locations: 🇺🇸
Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit, Durham, North Carolina, United States